Medical Management of Inflammatory Bowel Disease

Abstract

The past few decades have seen significant advancements in the medical management of both ulcerative colitis (UC) and Crohn's disease (CD). The previous dependence on steroids is no longer an acceptable strategy following the Food and Drug Administration approval for several new classes of medication. These medications include aminosalicylates, immunomodulators, biologics, and oral targeted small-molecule inhibitors. This article highlights several key trials and discusses modern treatment paradigms for both UC and CD based on disease severity.

Keywords: Biologic agents; Crohn’s disease; Immunomodulators; Inflammatory bowel disease; Small-molecule inhibitors; Ulcerative colitis.